Joyce Restad, DO
Family Medicine · Wasilla, AKNPI 1750594818
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $34.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$866
- Novo Nordisk$280
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$279
- GSK$274
- Teva Pharmaceuticals USA, Inc.$217
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,047100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $1,161 |
| AstraZeneca | 19 | $866 |
| Novo Nordisk | 9 | $280 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $279 |
| GSK | 5 | $274 |
| Teva Pharmaceuticals USA, Inc. | 3 | $217 |
| Axsome Therapeutics, Inc. | 6 | $200 |
| Merck | 6 | $200 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $171 |
| Nestle Healthcare Nutrition Inc. | 7 | $136 |
| Bridgebio Pharma, Inc. | 1 | $127 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Neurocrine Biosciences, Inc. | 1 | $115 |
| Exact Sciences | 4 | $111 |
| Lilly USA, LLC | 3 | $99 |
| Aimmune Therapeutics, Inc. | 4 | $92 |
| Astellas Pharma US Inc | 1 | $79 |
| Alkermes, Inc. | 1 | $78 |
| Pfizer | 4 | $70 |
| Eisai Inc. | 4 | $55 |
| Amarin Pharma, Inc. | 3 | $52 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| Biohaven Pharmaceuticals, Inc. | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Amgen | 2 | $30 |
| Mylan Specialty L.p. | 1 | $25 |
| Corium, LLC | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,047 in reported general payments places this provider in the 95th percentile of 334 family medicine providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 33 | $38,670 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,616 |
| MyrbetriqMirabegron | 15 | $8,379 |
| SynthroidLevothyroxine Sodium | 14 | $1,178 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $765 |
| Gabapentin | 45 | $762 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $731 |
| Atorvastatin Calcium | 52 | $516 |
| Alendronate Sodium | 43 | $410 |
| Escitalopram Oxalate | 26 | $360 |
| Levothyroxine Sodium | 31 | $313 |
| Hydrochlorothiazide | 43 | $277 |
| Citalopram HbrCitalopram Hydrobromide | 22 | $234 |
| Lisinopril | 49 | $222 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 12 | $202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $280 | $38,67033 claims |
| GSKTrelegy Ellipta | $274 | $13,61617 claims |
| Astellas Pharma US IncMyrbetriq | $79 | $8,37915 claims |
| AbbVieSynthroid | $1,161 | $1,17814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 family medicine providers in Alaska.
Other family medicine in Wasilla
- Ray KelleyWasilla$9K
- Frank GreathouseWasilla$7K
- Jessica JachimiecWasilla$6K
- Jim CookWasilla$6K
- Tracy SlagerWasilla$5K
- Wade EricksonWasilla$3K
- Valerie KrozelWasilla$3K
- Sarah HennemannWasilla$3K
- Nathan GeorgeWasilla$3K
- Jaron MinerWasilla$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.